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Three-dimensional tumor growth is dependent on
the perpetual recruitment of host blood vessels to the
tumor site. This recruitment process (mainly via
angiogenesis) is thought to be triggered, at least in
part, by the very same set of genetic alterations (acti-
vated oncogenes, inactivated/lost tumor suppressor
genes) as those responsible for other aspects of
malignant transformation (e.g., aberrant mitogen-
esis, resistance to apoptosis). Potent oncogenes are
able to deregulate expression of both angiogenesis
stimulators and inhibitors in cancer cells. For exam-
ple, mutant ras expression is associated with
increased production of vascular endothelial growth
factor (VEGF) and downregulation of thrombospon-
din-1 (TSP-1). Upregulation of VEGF and angiogen-
esis can also be induced by constitutive activation of
other oncogenic proteins (e.g., EGFR, Raf, MEK,
PI3K) acting at various levels on the Ras signaling
pathway. The mode and the magnitude of such pro-
angiogenic in¯uences can be signi®cantly modi®ed
by cell type (®broblastic or epithelial origin), epige-
netic factors (hypoxia, changes in cell density), and/
or presence of additional genetic lesions (e.g., pre-
ceding loss of p16 or p53 tumor suppressor genes).
Activated oncogenes (e.g., ras, src, HER-2) induce
co-expression of angiogenic properties concomi-
tantly with several highly selectable traits (increased
mitogenesis, resistance to apoptosis), a circumstance
that may accelerate selection of the angiogenic phe-
notype at the cell population level. On the other
hand oncogene-induced reduction in growth
requirements may also endow tumor cells with a
diminished (albeit not abrogated) dependence on
(close) proximity to blood vessels, i.e., with reduced
vascular dependence. Thus, oncogenes can impact sev-
eral interconnected aspects of cellular growth, survi-
val, and angiogenesis. Experimental evidence
suggests that, in principle, many of these properties
(including angiogenesis) can be simultaneously sup-
pressed (and tumor stasis or regression induced) by
effective use of the speci®c oncogene antagonists and
signal transduction inhibitors. Key words: anoikis/
apoptosis/cancer thrombospondin/Ras/vascular dependence/
VEGF. Journal of Investigative Dermatology Symposium
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LINKAGE BETWEEN ONCOGENES AND TUMOR
ANGIOGENESIS
A
berrant cellular architecture is a de®ning feature of
virtually all solid tumors. Transition from an orderly
cellular arrangement (cell layers, clusters, or single
cells) to a three-dimensionally unrestricted ``invasive''
growth pattern is a consistent correlate of malignant
progression in many types of human cancers, including melanoma
(Clark, 1991), skin cancer (Boone et al, 1992), colorectal carcinoma
(Fearon and Vogelstein, 1990), and many others. It is now evident
that such a change in cellular geometry could not be accomplished
solely due to changes in various intrinsic cancer cell properties (e.g.,
anchorage-independent growth, survival, morphologic transforma-
tion) but also relies on the collective ability of cancer cells to secure a
non-interrupted access to host-derived blood vessels (Folkman,
1990).
The source of virtually all clinical manifestations of cancer can
ultimately be traced to one or more of many genetic ``hits''
sustained by tumor cells during the course of disease progression
(Fearon and Vogelstein, 1990). Operationally, such transforming
genetic lesions can, at the cellular level, result in either ``gain of
function'' or a ``loss of function'' events. The former occur when a
proto-oncogene is activated or ampli®ed, whereas the latter affect
integrity and expression of tumor suppressor genes. An overt
malignant phenotype usually includes both types of changes
accumulated sequentially over a long period of time (Fearon and
Vogelstein, 1990). Interestingly, this pattern of genetic ``gains'' and
``losses'' is recapitulated within speci®c key biologic characteristics
of cancer cells, including those that govern the onset of tumor
angiogenesis (Hanahan and Folkman, 1996). For example,
endothelial cell recruitment and intratumoral capillary network
formation are thought to be initiated when expression of positive
angiogenesis regulators (stimulators) in tumor cells is turned ``on'',
and/or when production of endogenous angiogenesis inhibitors is
either turned ``off'' or downregulated (Hanahan and Folkman,
1996; Bouck et al, 1996). Among ``positive'' angiogenic stimuli, a
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more prominent role is ascribed to approximately a dozen
polypeptide growth factors and cytokines, the most intensively
studied of which are vascular endothelial growth factor/vascular
permeability factor (VEGF/VPF), basic ®broblast growth factor
(bFGF), acidic ®broblast growth factor (aFGF), and interleukin-8
(IL-8) (Folkman et al, 1997). On the other hand thrombospondin-1
(TSP-1) (Bouck et al, 1996), maspin (Zhang et al, 2000), and
interferon-a (Folkman et al, 1997) exemplify ``negative'' in¯uences
that are often lost concomitantly with the onset of tumor
angiogenesis (Hanahan and Folkman, 1996; Bouck et al, 1996).
Indeed, it is the net change in balance between angiogenesis
inhibitors and stimulators that ultimately sets in motion the
angiogenic reaction of host endothelial cells (Hanahan and
Folkman, 1996; Bouck et al, 1996). One of the more powerful
forces able to ``tilt'' this balance in favour of angiogenesis is
expression of activated oncogenes in tumor cells.
There are over 100 proteins that under certain conditions can act
as transforming oncogenes (Bishop, 1995). Ras oncoproteins in
particular, constitute an interesting case for the argument that
tumor angiogenesis has a genetic basis. Three existing ras genes
(H-ras, N-ras, or K-ras) encoding four protein isoforms (H-, N-,
K-rasA, and K-rasB, respectively) are known to be frequently
activated in human cancer (Khosravi-Far and Der, 1995). In
colorectal adenoma, activating K-ras mutations are found at
relatively early stages of tumor progression (Fearon and
Vogelstein, 1990) and their incidence strongly correlates with the
ability of adenomas to form large polypoid outgrowths (Minamoto
et al, 1994; Hasegawa et al, 1995). Such unlimited, three-
dimensional expansion of the tumor would be expected to depend
strictly on formation of new blood vessels (via angiogenesis, or
otherwise) (Folkman, 1990). Indeed, in many instances the
presence of mutant Ras oncoproteins has been formally shown to
be essential for continued tumor growth in vivo (Chin et al, 1999;
Shirasawa et al, 1993; Kohl et al, 1995). Furthermore, even in the
absence of an overt ras mutation, the biochemical activity of Ras
protein is often chronically elevated in cancer cells, and thus it can
contribute to induction and maintenance of their transformed
phenotype (Guha et al, 1997). Such permanent increases in Ras
activity (and GTP binding) are thought to result from upregulation,
constitutive activation, or mutation of upstream oncogenic proteins
such as members of the epidermal growth factor receptor (EGFR)
or platelet growth factor (PDGF) families (Marshal, 1995; Guha
et al, 1997; Hunter, 1997). It is well known that the Ras protein
controls several crucial signaling cascades (Khosravi-Far et al, 1998)
and thereby can alter expression of a large number of ``ras-
responsive'' genes (Chambers and Tuck, 1993; Bortner et al, 1993;
Zuber et al 2000), many of which could be relevant to triggering
tumor angiogenesis. This principle applies also to other oncogenic
proteins including c-fos (Robles et al, 1998; Marconcini et al,
1999), myc (Pelengaris et al, 1999; Meitar et al, 1996; Fotsis et al,
1999), myb (Bein et al, 1998), HPV-16 (Le Buanec et al, 1999),
E2a-Pbx1 (Fu et al, 1999), PTTG (Heaney et al, 1999), ODC
(Auvinen et al, 1997), polyoma middle T antigen (Sheibani and
Frazier, 1996), trkB (McGregor et al, 1999), v-p3K (Jiang et al,
2000), G-protein coupled receptors (Bais et al, 1998), and a number
of others (Bouck et al, 1996) (Table I).
THE ANGIOGENIC ``SWITCH'' IN CELLS HARBORING
AN ACTIVATED ONCOGENE: UPREGULATION OF
VEGF BY MUTANT RAS AS A PARADIGM
Constitutive expression of mutant H-ras oncogene in immortalized
rat intestinal epithelial cells (IEC-18) leads, in one step, to an
overtly tumorigenic phenotype in vivo (Buick et al, 1987; Rak et al,
1995). In cases such as this, apparent formation of large tumors
(greater than 10 mm in diameter) would not have been achieved
under avascular conditions (Folkman, 1990), and hence we
surmised that ras transformation itself must somehow result in
adequate tumor neovascularization (Rak et al, 1995). In support of
this possibility, conditioned medium of ras-transformed cells was
found to contain an activity capable of sustaining the growth and
survival of primary human endothelial cells (HUVEC) in vitro (Rak
et al, 1995). An important component of this pro-angiogenic
activity was subsequently identi®ed as VEGF on the basis of the
following criteria: (i) the activity could be neutralized by anti-
VEGF antibodies (Rak et al, 1995), (ii) the conditioned medium of
ras-transformed cells was able to activate VEGF receptor-2/¯k-1
(Grugel et al, 1995), (iii) ras transformation strictly coincided with
upregulation of immunodetectable VEGF protein and mRNA
(Rak et al, 1995; Grugel et al, 1995; Rak et al, 2000), (iv) transient
expression of mutant H-ras in IEC-18 cells under the control of a
metallothionein or tetracycline-repressible promoter led to a
corresponding increase in VEGF levels (Fig 1, Rak et al, 1995),
(v) genetic disruption of the mutant K-ras allele in two human
colorectal cancer cell lines (Shirasawa et al, 1993) led to a dramatic
reduction in tumor forming capacity and to several fold down-
regulation of VEGF (Rak et al, 1995). Furthermore, pharmacologic
inhibition of Ras activity by treatment with farnesyl transferase
inhibitors (FTI) was able to attenuate ras-dependent increases in
VEGF production in various experimental systems. In one such
study human astrocytoma cells have been found to express
constitutively activated Ras protein even in the absence of gene
Table I. Impact of oncogenes on tumor angiogenesisa
Oncogeneb Implicated pro-angiogenic activity References
K-ras, H-ras VEGF upregulation, TSP-1 downregulation Rak et al, 1995; Grugel et al, 1995; Rak et al, 2000; Zabrenetzky et al, 1994
v-src VEGF upregulation, TSP-1 downregulation Rak et al, 2000; Mukhopadhyay et al, 1995; Slack and Bornstein, 1994
c-myb TSP-2 downregulation Bein et al, 1998
N-myc angiogenic properties in neuroblastoma Meitar et al, 1996; Fotsis et al, 1999
c-myc angiogenic properties in epidermis Pelengaris et al, 1999
HER-2 VEGF upregulation Viloria-Petit et al, 1997
EGFR VEGF, bFGF, IL-8 upregulation Viloria-Petit et al, 1997; Perrotte et al, 1999
PyMT TSP-1 downregulation Sheibani and Frazier, 1996
c-fos VEGF expression Saez et al, 1995
trkB VEGF downregulation McGregor et al, 1999
HPV-16 secretion of VEGF and IFN-a Le Buanec et al, 1999; Lopez-Ocejo et al, 2000
v-p3k VEGF production and angiogenesis Jiang et al, 2000
ODC novel angiogenic factor Auvinen et al, 1997
PTTG1 VEGF and bFGF upregulation Heaney et al, 1999
E2a-Pbx1 induction of mouse angiogenin-3 Fu et al, 1999
aFor further review see Hanahan and Folkman (1996) and Bouck et al (1996).
bNomenclature: HER-2/ErbB-2/neu, homologue of EGFR; EGFR, epidermal growth factor receptor; HPV-16, human papilloma virus; PyMT, polyoma middle T
antigen, ODC-ornithine decarboxylase; v-p3K, oncogenic variant of PI3K p110; PTTG1, pituitary tumor transforming gene 1; E2a+Pbx1, chimeric leukemia oncogene.
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mutations (Guha et al, 1997). Transfection of a dominant negative
mutant of ras (N17ras) or treatment with FTI led in this case to a
marked downregulation of VEGF mRNA and protein (Feldkamp
et al, 1999a,b).
VEGF AS A MEDIATOR OF ONCOGENE DEPENDENT
TUMOR ANGIOGENESIS
Endogenous production of VEGF by cancer cells is, at least in
some instances, absolutely required for tumor growth and
angiogenesis. This notion is supported by several lines of
evidence including: (i) upregulation of VEGF in the majority of
human tumors (Brown et al, 1997); (ii) suppression of
tumorigenic properties in cancer cells in which VEGF
production had been obliterated by anti-sense (Saleh et al,
1996; Ellis et al, 1996; Cheng et al, 1996; Claffey et al, 1996;
Masood et al, 1997; Oku et al, 1998; Nguyen et al, 1998; Im
et al, 1999) or gene knock-out (Ferrara et al, 1996) approaches;
(iii) signi®cant therapeutic ef®cacy of anti-VEGF antibodies
(Kim et al, 1993; Warren et al, 1995; Ferrara and Davis-Smyth,
1997), soluble VEGF receptors (Ferrara and Davis-Smyth, 1997;
Goldman et al, 1998; Lin et al, 1998; Siemeister et al, 1999), or
VEGF receptor inhibitors (Ferrara and Davis-Smyth, 1997;
Millauer et al, 1994, 1996; Witte et al, 1998; Shaheen et al,
1999; Fong et al, 1999); (iv) concomitant inhibition of VEGF
expression and tumor formation by agents targeting oncogenes
[e.g., Ras farnesyl transferase inhibitors (Rak et al, 1995;
Feldkamp et al, 1999a, b), antibodies blocking the activity of
EGFR (Viloria-Petit et al, 1997; Perrotte et al, 1999), or HER-
2 (Viloria-Petit et al, 1997)].
Such results raise the question of whether VEGF is indeed
indispensable for tumor formation under the in¯uence of mutant
oncogenes. In order to address this speci®c issue two independent
human colorectal carcinoma cell lines (DLD-1 and HCT-116)
harboring mutant K-ras oncogene were subjected to transfection
with VEGF121 anti-sense cDNA. The resulting 3±4-fold reduction
in VEGF levels was similar in magnitude to what had previously
been achieved through deletion of the mutant K-ras allele in the
same cells (Rak et al, 1995). Even such incomplete VEGF
downregulation severely attenuated the tumor forming potential
of all VEGF suppressed clones analyzed (Okada et al, 1998). This
result (Okada et al, 1998), and at least two other independent
studies (Shi and Ferrara, 1999; Grunstein et al, 1999) (Table II),
suggest that VEGF expression is often (but not always) required for
tumor formation in the context of this particular oncogene. It
remains to be established to what extent this observation can be
generalized.
Whereas angiogenic pro®ciency through VEGF upregulation, or
through other similar changes, is necessary for the three-
dimensional tumor growth, it clearly is not suf®cient. Over-
expression of VEGF121 in K-ras disrupted variants of DLD-1 and
HCT116 cells (DKs-8 and HKh-2, respectively) failed to fully
restore tumor forming capacity of these cells (Okada et al, 1998).
Similarly, a recent study in which a mutant ras transgene was
expressed in tumors of melanocytic origin suggested that the
presence of VEGF at the tumor site cannot substitute for the
pleiotrophic effect of the oncogene on tumor growth and
maintenance (Chin et al, 1999). Furthermore, it is well established
that obliteration of the pro-mitogenic or anti-apoptotic activities of
mutant ras can also severely affect tumor formation regardless of the
angiogenic status. For example, expression of mutant ras in murine
keratinocytes lacking a functional cyclin D1 gene leads to a
signi®cant impairment in tumor growth and aggressiveness (Robles
et al, 1998). Likewise, the tumor forming ability of ras-transformed
IEC-18 cells is diminished when the wild-type levels of Ras-
responsive apoptosis regulators (Bak, Bcl-xL) are selectively
restored (Rosen et al, 1998). Thus, three-dimensional tumor
growth in vivo appears to depend on simultaneous changes in
several fundamental cellular characteristics including deregulation
of cell cycle control, increased survival, and activated angiogenesis.
Figure 1. Impact of mutant oncogenes on expression of VEGF and
TSP-1 in epithelial cells. (A) Upregulation of VEGF and down-
regulation of TSP-1 at the mRNA level by constitutive expression of
mutant H-Ras in two independent clones of IEC-18 cells (RAS-3, RAS-4)
(left-hand panel). Expression of VEGF and TSP-1 in two independent clones
of IEC-18 cells engineered to transiently express mutant H-Ras under
control of a tetracycline-repressible promoter (right-hand panel). Withdrawal
of the drug (tet-) for 48 h leads to expression of VEGF but has little impact
on levels of TSP-1 mRNA. (B) Upregulation of VEGF in clones of IEC-18
cells constitutively overexpressing v-src (SRC-2, SRC-3). Transformation
with v-src has little impact on TSP-1 mRNA levels. (C) Relative
tumorigenic capacity of H-ras and v-src transformed sublines of IEC-18 cells
(upon injection of 2 3 106 cells s.c.). Parental IEC-18 cells or their non-
transformed clones (IEC-18/4A, IEC-18/4B) are non-tumorigenic,
whereas their counterparts expressing the respective oncoproteins grow
rapidly in mice. H-ras transfectants appear to be somewhat more
tumorigenic, possibly because they do not retain expression of TSP-1.
Table II. Evidence supporting the essential role of tumor cell-derived VEGF during tumor formation under the in¯uence of
mutant ras oncogenes
Approach Observation Reference
VEGF anti-sense transfection Enforced downregulation of VEGF expression abrogated Okada et al, 1998
K-ras-dependent tumorigenicity of human colorectal cancer cells.
VEGF gene knock-out Transfection of VEGF±/± ES cells with mutant ras did not rescue Shi and Ferrara, 1999
the tumorigenic phenotype.
VEGF gene knock-out v-H-ras transformed VEGF±/± mouse embryo ®broblasts are Grunstein et al, 1999
de®cient in tumor forming ability.
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MOLECULAR MEDIATORS OF RAS-DEPENDENT VEGF
UPREGULATION
The realization that VEGF can contribute to ras-dependent tumor
formation naturally leads to the idea that oncogene-directed signal
transduction inhibitors may possess an indirect anti-angiogenic
activity (Rak et al, 1995; Kerbel et al, 1998). Therefore, it seems
worthwhile to delineate more precisely the pathway(s) participating
in oncogene-dependent upregulation of VEGF, because such
inquiry could potentially reveal several suitable molecular targets
for direct or indirect inhibition of tumor angiogenesis (Fig 2).
In general, regulation of VEGF expression and activity is rather
complex and can be in¯uenced at multiple levels (Ferrara and
Davis-Smyth, 1997). These include regulation of gene transcription
(Tischer et al, 1991; Beerepoot et al, 1996; Forsythe et al, 1996;
Mazure et al, 1997), mRNA stability (Levy et al, 1996, 1997; Stein
et al, 1995; Dibbens et al, 1999), splicing (Tober et al, 1998) as well
as the rate of translation (Kevil et al, 1996; Stein et al, 1998; Akiri
et al, 1998; Scott et al, 1998) or post-translational events (DiSalvo
et al, 1995).
The principal dif®culty in establishing the exact mode of VEGF
regulation in cells harboring a particular oncogene lies in the
complexity of the signaling pathways that could potentially be
involved (Hunter, 1997). In the case of mutant ras, not only large
numbers of protein targets and signaling mediators must be
considered, but also the fact that some of the phenotypic changes
attributed to ras transformation are induced indirectly, e.g., by
activation of autocrine growth factor circuitry driven by members
of the transforming growth factor-a (TGF-a) family (among
others). Furthermore, the effect of the oncogene can be modi®ed
by accompanying genetic and epigenetic in¯uences such as the
presence of other genetic changes (including other oncogenes or
tumor suppressor genes), cell type, microenvironmental conditions
(hypoxia) or paracrine stimulation (Rak et al, 2000). In this regard,
our previous studies on IEC-18 intestinal epithelial cells indicated
that the relationship between expression of mutant ras and
induction of VEGF is not mediated in an autocrine manner,
because the conditioned medium of ras-transformed IEC-18 cells
(RAS-3) was unable to induce VEGF production in their non-
transformed counterparts (Rak et al, 2000). Moreover, the ras-
dependent increase in VEGF expression could not be abrogated by
an anti-TGF-a antibody or genistein, a receptor tyrosine kinase
inhibitor able to block EGFR (Rak et al, 2000). On the other hand,
expression of the activated form of raf (Grugel et al, 1995) or MEK-
1 (Milanini et al, 1998; Rak et al, 2000) in NIH3T3 cells or hamster
CCL39 ®broblasts was found to be suf®cient to substitute for
mutant ras with respect to upregulation of VEGF. In addition,
treatment of ras-transformed ®broblasts with a MEK-1 inhibitor
(PD98059) normalized their VEGF expression (Milanini et al,
1998; Rak et al, 2000). In contrast, in H-ras-transformed epithelial
cells (RAS-3), treatment with PD98059 produced only a marginal
effect. In such cells a signi®cant decrease in VEGF mRNA and
protein expression was achieved in the presence of the powerful
inhibitor of phosphatidyl inositol 3¢-OH kinase (PI3K) known as
LY294002 (Rak et al, 2000). Combination treatment with both the
MEK-1 and the PI3K inhibitors was of even greater potency,
suggesting that both of these effector pathways contributed in some
way to upregulation of VEGF in ras-transformed epithelial cells.
Collectively, these results point to a complex and cell type speci®c
mode of VEGF regulation by mutant ras oncogene (Rak et al,
2000).
CO-REGULATION OF VEGF EXPRESSION BY GENETIC
AND EPIGENETIC FACTORS
The analysis of ras-dependent upregulation of VEGF under
different conditions provides an informative example of how
genetic and epigenetic in¯uences can cooperate in triggering tumor
angiogenesis. For instance, in NIH3T3 ®broblasts, expression of
mutant H-ras was shown to synergize with hypoxia in stimulating
the activity of the VEGF promoter via PI3K-dependent activation
of a transcription factor known as hypoxia inducible factor-1 (HIF-
1) (Mazure et al, 1997). A similar conclusion was reached in an
earlier study using an H-ras transformed murine endothelial cell line
(Arbiser et al, 1997). Also, the expression of activated neu/HER-2
oncogene in NIH3T3 cells and exposure to hypoxia led to a
synergistic VEGF upregulation (Viloria-Petit et al, 1997). In
contrast, treatment of K-ras positive HCT-116 colorectal carcino-
ma cells with the hypoxia mimetic CoCl2 failed to produce an
increase in VEGF production (Okada et al, 1998) even though such
treatment can readily activate HIF-1 (Jiang et al, 1997). In this
context it is interesting to note that in mouse embryos de®cient for
HIF-1 activity due to inactivation of one of its subunits (ARNT/
HIF-1b), VEGF is downregulated in all tissues except for the gut
epithelium (Maltepe et al, 1997). This observation suggests the
possibility of alternative tissue/intestine speci®c pathways of VEGF
regulation under hypoxic conditions. Furthermore, transformation
with certain oncogenes, such as v-src, can replace or mimic hypoxia
Figure 2. Multiple approaches to disrupt oncogene-dependent angiogenesis. Anti-angiogenic effects can be achieved by using direct oncogene
inhibitors acting on the tumor cell compartment (1), e.g., mutant Ras or a related target can be targeted by farnesyl transferase inhibitors (FTI), HER-2 can
be blocked by herceptin, EGFR can be inhibited by speci®c monoclonal antibodies (C225) or small molecular weight pharmacological inhibitors (AG1479).
Similarly, the angiogenic capacity of the tumor cell compartment can be obliterated by inhibiting oncogene-activated signaling pathways (2) or their pro-
angiogenic molecular targets such as VEGF (3). Targeting angiogenic mediators (VEGF) or their receptors represent an intermediate approach directed
against both tumor cells and angiogenic endothelial cells. Direct targeting of the endothelial cell compartment can be achieved by using protein angiogenesis
inhibitors (endostatin, angiostatin) and/or anti-angiogenic (``metronomic'') scheduling of chemotherapy (4). Endothelial cells are also responsive to signal
transduction inhibitors (5) (Gu et al, 1999).
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as a stimulant of HIF-1 activity and VEGF expression (Jiang et al,
1997). The expression of dominant negative c-src (srcRF) in
NIH3T3 cells was shown to inhibit hypoxia-induced upregulation
of VEGF (Mukhopadhyay et al, 1995). More recent studies suggest
that the pro-angiogenic consequences associated with the loss of the
p53 tumor suppressor gene may also involve increase in HIF-1
levels and activity (Ravi et al, 2000). However, the exact
signi®cance of HIF-1 stimulation for tumor growth and angiogen-
esis still remains to be ®rmly established especially in light of the
®nding that embryonic stem cells deleted for HIF-1a are not
inhibited in their tumor forming capacity as compared with their
wild-type counterparts (Carmeliet et al, 1998). Indeed, their growth
is actually stimulated, somewhat counter-intuitively, as a result of
increased apoptosis resistance (Carmeliet et al, 1998).
Another interesting epigenetic in¯uence that can upregulate
VEGF expression in tumor cells is growth under high cell density
conditions (Koura et al, 1996). Malignant transformation appears to
be absolutely required for such VEGF stimulation as parental, non-
transformed IEC-18 cells do not upregulate VEGF in con¯uent
cultures, whereas such upregulation occurs readily in their ras-
transformed (RAS-3) counterparts (Rak et al, 2000). Interestingly,
RAS-3 cells grown in high density cultures also become less
responsive to treatment with LY294002 (PI3K inhibitor) in terms
of reducing their VEGF production (Rak et al, 2000).
INTERDEPENDENCE OF ONCOGENES AND TUMOR
SUPPRESSOR GENES IN REGULATION OF TUMOR
ANGIOGENESIS
Cell transformation by a given activated oncogene is usually
conditional upon pre-existing genetic alterations (Hahn et al, 1999).
For example, while mutant ras can readily transform immortalized
®broblastic cell lines, expression of this oncogene in primary
cultures leads to growth arrest and induction of cellular senescence
(Serrano et al, 1995, 1997). This is largely attributed to ras-
dependent upregulation of the p16/INK4a cyclin-dependent
kinase inhibitor, a tumor suppressor gene that apparently acts as a
``built-in'' safety device to prevent cell transformation (Serrano et al,
1995, 1997). Genetic inactivation of p16/INK4a is therefore
required for ras-induced transformation of murine ®broblasts
(Serrano et al, 1997) or melanocytes (Chin et al, 1999), and
cooperates with activation of the EGFR oncogene in the
generation of astrocytomas in mice (Holland et al, 1998), and
possibly in humans (Moulton et al, 1995).
Interestingly, in high grade astrocytoma and glioblastoma many
features of cellular transformation, including dramatic upregulation of
VEGF, have been linked to constitutive activation of the Ras
signaling pathway (Guha et al, 1997; Feldkamp et al, 1999). In this
regard it is obvious to ask whether angiogenesis in general, and VEGF
regulation in particular, is in any way in¯uenced by a bona ®de cell
cycle inhibitor such as p16/INK4a. In order to address this question
we utilized a model system in which p16/INK4a could be
conditionally expressed in U343 human astrocytoma cells in a
tetracycline-repressible manner (Dirks et al, 1997). In the presence of
tetracycline, U343/p16tet cells express high levels of secretable
VEGF (Fig 3); however, upon withdrawal of the drug and
commensurate induction of p16/INK4a expression, VEGF secretion
is dramatically inhibited in a time dependent manner (Fig 3). Similar
®ndings were also obtained by infecting astrocytoma cells in culture
with an adenoviral expression vector encoding p16/INK4a (Harada
et al, 1999). These results are not simply re¯ective of changes in cell
cycle progression because growth arrest in con¯uent cultures of
U343/p16tet is actually accompanied by an increase in VEGF
production (Sheehan, Rak, and Kerbel, unpublished observation). It
is of considerable interest to ask whether and how induction of the
angiogenic phenotype in cells transformed with oncogenes can be
modulated by various tumor suppressors, e.g. p16/INK4a, p53, APC,
PTEN, or VHL. In this regard Mukhopadhyay et al (1995) have
observed that v-srcdependent activationof the VEGFpromoter canbe
suppressed by co-transfection of wild-type p53 .
In addition to co-regulation of angiogenesis effector molecules
(e.g., VEGF) by concerted action of oncogenes and tumor
suppressor genes, it is also worth considering their sequential or
cumulative in¯uence on tumor angiogenesis. For example, Volpert
et al (1997) have shown that in ®broblasts derived from patients
affected by the Li±Fraumeni syndrome (which involves a germ-line
loss of one p53 allele), a complete angiogenic switch may require
two discrete stages. First, loss of the remaining p53 allele causes a
dramatic decrease in expression of TSP-1 and a slight upregulation
of VEGF. Subsequent expression of mutant ras leads to a boost in
VEGF production and overt expression of VEGF-dependent
angiogenic properties (Volpert et al, 1997). In light of such
observations and with the overall logic of multistep tumor
progression in mind it is reasonable to propose that the deregulation
of angiogenic properties of tumor cells is a continuum (``angiogen-
esis progression'') rather than what is often perceived as an apparent
single step event (i.e., an angiogenic ``switch'') (Rak et al, 1996).
COMPLEX NATURE OF ONCOGENE-DRIVEN TUMOR
ANGIOGENESIS
Severe angiogenic de®ciency induced by disruption of even one
VEGF allele in mice led to the notion that this growth factor is
central and indispensable for all processes involving blood vessel
formation (Ferrara et al, 1996; Carmeliet et al, 1996; Ferrara and
Davis-Smyth, 1997). In some instances, however, elevated
endogenous production of VEGF by tumor cells may not be
suf®cient, or even required, for tumor growth and angiogenesis
(Chin et al, 1999; Okada et al, 1998; Fukumura et al, 1998; Yoshiji
et al, 1997). This can be explained, at least in part, by the ability of
mutant ras (and possibly other oncogenes) to deregulate expression
of several different angiogenesis stimulators and inhibitors in various
types of cells (Table III). Another circumstance that may, at least in
some cases, diminish the impact of tumor cell-derived VEGF on
angiogenesis is the production of this growth factor by host stromal
cells (Bais et al, 1998; Fukumura et al, 1998; Hlatky et al, 1994;
Coussens et al, 1999). In this regard, we observed that injection of
v-H-ras transformed, adult mouse dermal ®broblasts into SCID
mice resulted in tumor formation regardless of whether the cells
were of VEGF+/+ or VEGF±/± genotype. This was accompanied
by an appreciable in®ltration of host stromal cells (Rak et al,
unpublished). Tumor angiogenesis was clearly driven by the action
of the oncogenic ras (non-transformed cells did not form
angiogenic tumors); however, the oncogene-dependent pro-
Figure 3. Inhibition of VEGF production in human astrocytoma
cells by p16/INK4a tumor suppressor gene. U343 cells, which are
known to produce VEGF in a ras-dependent manner (Feldkamp et al,
1999), have been engineered to express p16/INK4a under control of a
tetracycline-repressible promoter (Dirks et al, 1997). Withdrawal of
tertracycline (tet-) in tissue culture resulted in re-expression of p16/INK4a
and suppression of VEGF production by U343 tumor cells.
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angiogenic mechanism could in this case involve other growth
factors and/or recruitment of VEGF positive host stromal
®broblasts (Rak et al, unpublished observation).
The question of how tumors acquire their microvasculature has
recently become a subject of considerable interest as well as
controversy. In this regard, the principal, if not exclusive, role was
traditionally ascribed to the process known as ``sprouting angiogen-
esis'' (Folkman, 1990), de®ned by directional deployment of aligned
endothelial cell cohorts (``sprouts'') from pre-existing capillaries or
post-capillary venules (Paweletz and Knierim, 1989). A series of
recent studies point to several possible alternative modes of tumor
neovascularization, such as vascular intusussception (Burri, 1991),
seeding and incorporation of bone marrow-derived endothelial cell
progenitors (Roberts et al, 1994), vascular ``cooption'' (Holash et al,
1999), or, still highly controversial, ``vascular mimicry'' (Maniotis
et al, 1999; McDonald et al, 2000). Although the details of the
molecular regulation and the relative contribution of these various
processes to tumor neovascularization remain to be established, they
too (by de®nition) would fall under direct or indirect control of
genetic changes in tumor cells, including mutant oncogenes.
``COLLATERAL'' SELECTION OF THE ANGIOGENIC
PHENOTYPE IN THE TUMOR CELL POPULATION
It is reasonable to assume that an angiogenic ``switch'' in the
growing tumor would require accumulation of a certain number (a
``critical mass'') of angiogenic tumor cells in order to create a
suf®cient concentration gradient of stimulatory growth factors. In
other words, it would take more than one angiogenically
competent tumor cell (perhaps a majority) to trigger effective
tumor neovascularization. It is unclear how exactly an enrichment
in such cells could be realized.
Indeed, an ``angiogenic phenotype'' on its own would be
expected to confer only a relatively weak selective growth
advantage upon individual tumor cells (Jouanneau et al, 1994).
The presence of a blood vessel capillary within a given tumor
microdomain, incipient tumor, or dormant metastasis would be
unlikely to favor growth of one speci®c cancer cell (clone) over
another, regardless of its angiogenic phenotype (Miller and
Heppner, 1990). Rather, access to such a new capillary would be
``altruistically'' shared among heterogenous tumor cells populating
this particular site (Fig 4, left panel). In contrast, a cell-autonomous
(``sel®sh''), selective growth advantage would clearly be conferred
upon individual tumor cells expressing intrinsically higher mitotic
activity, reduced growth factor requirements, or resistance to
apoptosis under microenvironmental stress conditions.
The coexistence of various ``sel®sh'' (e.g., apoptosis resistance) or
``altruistic'' (e.g., angiogenic competence) tumor cell properties is
somewhat paradoxical as it is not obvious how the latter are
maintained in the population. A prototypic experiment that might
shed some light on this issue came from our earlier studies on the
regulation of epithelial cell survival under anchorage-independent
Table III. Changes in expression of multiple angiogenesis regulators in cells harboring a mutant ras oncogene
Factora Bioactivity Angioactivity Impact of ras Reference
VEGF growth factor stimulator upregulation Rak et al, 1995; Grugel et al, 1995
bFGF growth factor stimulator upregulation Iberg et al, 1989
TGF-a growth factor stimulator upregulation Marshall et al, 1985
TGF-b growth factor stimulator upregulation Glick et al, 1991
TNF-a cytokine stimulator (at low conc.) upregulation Castelli et al, 1994
G-CSF cytokine stimulator upregulation Demetri et al, 1990
IGF-1 growth factor stimulator upregulation Dickson et al, 1987
PDGF growth factor stimulator upregulation Bowen-Pope et al, 1984
OPN ECM component stimulator upregulation Craig et al, 1988
TSP-1 ECM component inhibitor downregulation Zabrenetzky et al, 1994
TIMP MMP inhibitor inhibitor downregulation Chambers and Tuck, 1993
PGE prostaglandin stimulator upregulation Marshall et al, 1985
aAbbreviations: VEGF, vascular endothelial growth factor; bFGF, basic ®broblast growth factor; TGF-a, transforming growth factor alpha; TGF-b, transforming growth
factor beta; TNF-a, tumor necrosis factor alpha; G-CSF, granulocyte colony stimulating factor; IGF-1, insulin like growth factor 1; PDGF, platelet derived growth factor;
OPN, osteopontin; TSP-1, thrombospondin 1; TIMP, tissue inhibitor of metalloproteinases; PGE, prostaglandin E
Figure 4. Selection of the angiogenic pheno-
type in the heterogenous tumor cell popula-
tion. ``Autonomous'' expression of the angiogenic
phenotype by a subpopulation of tumor cells is
likely to be associated with a weak selective
growth advantage. In such a case the access to
blood vessels would be shared among various
clones of tumor cells. Expression of a transforming
oncogene (e.g., ras or v-src) would endow cells
with a ``clustered'' phenotype comprising weakly
selectable properties (angiogenic capacity) and
strongly selectable traits (apoptosis resistance,
growth factor independence). Within such a
``clustered'' phenotype, angiogenic properties may
become dominant in the population.
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culture conditions (Rak et al, 1995, 1999). In such three-
dimensional (spheroid) cultures, non-tumorigenic IEC-18 cells
invariably succumbed to a massive and rapid form of programmed
cell death known as ``anoikis''. Their tumorigenic, H-ras, or v-src
transformed counterparts were completely anoikis-resistant (Rak
et al, 1995, 1999). In order to establish whether acquisition of
anoikis-resistance could, in its own right, confer any degree of
tumorigenic capacity, IEC-18 cells were subjected to a lengthy in
vitro selection in order to obtain variants with increased anchorage-
independent survival capacity (Fig 5A). Indeed, two series of such
anoikis resistant variants (designated AR1 and AR2) were obtained,
and shown to form slow growing tumors in nude mice. Somewhat
unexpectedly, tumor growth continued beyond sizes achievable
without the onset of angiogenesis (Fig 5C) and resulted in
formation of large, apparently vascular outgrowths (500±1500 mg).
Furthermore, anoikis resistant (AR) variants exhibited a constitu-
tive upregulation of VEGF expression (Fig 5B) even without prior
exposure to in vivo (angiogenesis-dependent) growth conditions
(Rak et al, 1999). Thus, resistance of AR variants to ``anoikis''
appeared to co-segregate with pro-angiogenic properties, even
though the latter phenotype would have been of no biologic
signi®cance at the time of its ``collateral'' selection in tissue culture
(Rak et al, 1999). There is a striking similarity between this
spontaneously induced pleiotrophic alteration (of still unknown
molecular nature), and the complex phenotype induced in IEC-18
cells (and in other cell types) by mutant ras, src, and other
transforming oncogenes (Rak et al, 1995). In both cases, the
angiogenic phenotype is linked to highly selectable traits such as
apoptosis resistance and reduced growth requirements. Such
genetically determined co-expression and co-selection of various
tumor cell properties may ultimately allow manifestation of the
angiogenic phenotype at the level of the tumor cell population
(Rak et al, 1999).
CHANGES IN RELATIVE VASCULAR DEPENDENCE OF
TUMOR CELLS EXPRESSING TRANSFORMING
GENETIC ALTERATIONS
Although tumors that have grown to a certain size may be
competent to induce a vigorous angiogenic response, the resulting
vasculature is often disfunctional (Jain, 1990). Tumor cell
proliferation decreases dramatically with increasing distances from
neighboring blood vessels (Tannock, 1968) due to hypoxia
(Thomlinson and Gray, 1955), glucose deprivation and insuf®cient
concentrations of nutrients, growth and survival factors, both
blood-borne (Folkman, 1990) and endothelium-derived (Rak et al,
1996). It is noteworthy that tumor cell dependence on exogenous
supply of oxygen, growth, and survival factors is often gradually
diminished during tumor progression (Bedi et al, 1995) and thereby
coincides with expression of transforming oncogenes (Hanahan and
Weinberg, 2000) or loss of tumor suppressor genes (Graeber et al,
1996; Hanahan and Weinberg, 2000). Consequently, the relative
reliance of tumor cells on immediate proximity to blood vessels
may also decrease as a function of the severity of the oncogene-
induced cellular transformation (Fig 6) (Rak and Kerbel, 1996).
This is apparent in the case of two tumorigenic clones of IEC-18
cells expressing either high (RAS-7) or low (RAS-3) levels of H-
Ras oncoprotein (Rak et al, 1995). In mixed tumors composed of
RAS-7 and RAS-3 populations the latter (less malignant) cell type
is ultimately restricted to areas immediately adjacent (proximal) to
the tumor vasculature, whereas RAS-7 cells can be found
throughout the tumor including its most hypoxic (distal) regions
(Rak et al, 1996). The ability of RAS-7 cells to grow and survive in
areas distant from blood vessels is consistent with their overall
greater survival capacity and mitotic activity under a variety of stress
conditions (Rak et al, 1996) as compared with their less transformed
and more ``vascular-dependent'' RAS-3 counterparts. More recent
studies highlight other possible mechanisms of altered vascular
dependence in tumors. For instance, certain strains of embryonic
Figure 5. ``Collateral'' expression of tumorigenic and angiogenic
properties by epithelial cells selected for resistance to ``anoikis''.
Non-tumorigenic epithelial cells (IEC-18) were subjected to ten cycles of
anoikis induction and recovery in vitro (A). This procedure resulted in
derivation of anoikis-resistant cellular variants (AR1.10, AR2.10), which
were found to spontaneously over-express VEGF (B) without any exposure
to angiogenesis-dependent growth conditions. Anoikis-resistant variants
were also tumorigenic in vivo (C).
Figure 6. Pleiotrophic consequences of targeting oncogenes.
Targeting oncogenes would be expected to simultaneously block multiple
features of cellular transformation including mitogenesis, resistance to
apoptosis, and angiogenic capacity. Such treatment would also reverse the
oncogene-dependent decline in vascular dependence of tumor cells (see
text).
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stem cells de®cient for HIF-1a (HIF-1a±/±), and therefore
incapable of hypoxic induction of VEGF, produced tumors that,
despite much reduced vascular density grew at an accelerated rate
relative to their HIF-1a+/+, VEGF-positive counterparts
(Carmeliet et al, 1998). This paradoxical outcome has been
attributed to pro-apoptotic and anti-mitotic properties of activated
HIF-1 (Carmeliet et al, 1998). Moreover, in mixed tumors
composed of HIF-1a±/± and HIF-1a+/+ ES cells the latter were
preferentially localized to areas surrounding well perfused blood
vessels (Yu et al, 2000).
Another, perhaps even more relevant, molecular change that can
selectively augment tumor cell survival under hypoxic conditions
(i.e., at a greater distance from the vasculature) is the loss of the p53
tumor suppressor gene (Graeber et al, 1996). It is intriguing that this
molecular alteration is often found at the late stages of colorectal
cancer progression (Fearon and Vogelstein, 1990) when poor
perfusion and increasing hypoxia may exert a signi®cant selective
pressure on tumor cells to become less ``vascular dependent''. These
sorts of considerations lead to a prediction that with tumor
progression a decrease in vascular dependence of cancer cells may
allow continuous tumor growth even at relatively lower blood
vessel densities as compared with conditions present in the original
lesion (Rak et al, 1996; Rak and Kerbel, 1996). Nevertheless, in the
context of long-term treatment with anti-angiogenic agents the
possible quantitative reduction in vascular dependence of tumor
cells would be expected to have only a limited impact on
therapeutic ef®cacy.
CONCLUSIONS
Diverse functional changes induced in cancer cells by activated
oncogenes are crucial for maintenance of various aspects of three-
dimensional tumor growth in vivo (Shirasawa et al, 1993; Chin et al,
1999). A valuable lesson that can be learned from analysis of such
pleiotrophic in¯uences is that selective targeting of oncogenes (if
practically achievable) could exert a powerful anti-cancer effect
through at least three different mechanisms (Fig 6) namely: (i) direct
growth arrest and induction of tumor cell apoptosis (through
``anoikis'' and other mechanisms), (ii) obliteration of the angiogenic
phenotype in tumor cells, and (iii) increase in vascular dependence.
Exploratory studies in targeting oncogenes by using various
pharmacologic antagonists, signal transduction inhibitors, and
neutralizing antibodies have already begun (Rak et al, 1995;
Feldkamp et al, 1999; Brown et al, 1997; Viloria-Petit et al, 1997;
Charvat et al, 1999). An exciting possibility is that inhibitors of
oncogenic signaling may synergize with a number of other anti-
angiogenic modalities including direct acting anti-angiogenic agents
(e.g., endostatin) or anti-vascular regimens of low dose anti-cancer
chemotherapy (Klement et al, 2000; Browder et al, 2000).
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